Enbrel Etanercept Solution for Injection

1. Indications and Usage
Rheumatoid Arthritis: Treatment of moderate to severe active rheumatoid arthritis in adults and children (≥2 years old).
Ankylosing Spondylitis: Treatment of adult patients with active ankylosing spondylitis.
Psoriatic Arthritis: Treatment of adult patients with active psoriatic arthritis.
Chronic Plaque Psoriasis: Treatment of adult patients with severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Juvenile Idiopathic Arthritis: Treatment of polyartiform juvenile idiopathic arthritis in children (≥2 years old).
2. Dosage and Administration
Route of Administration: For Subcutaneous (SC) Injection ONLY.
Recommended Dosage (Adults):
Rheumatoid Arthritis/Ankylosing Spondylitis/Psoriatic Arthritis: 25 mg administered once weekly or 50 mg administered once weekly.
Chronic Plaque Psoriasis: 50 mg administered twice weekly for 12 weeks, followed by 25 mg twice weekly or 50 mg once weekly for maintenance.
Recommended Dosage (Pediatrics):
Juvenile Idiopathic Arthritis: 0.8 mg/kg once weekly (maximum 50 mg/week).
Critical Administration Instructions:
Site Selection: Administer in the abdomen (avoiding the 5 cm periumbilical area) or thigh. Rotate injection sites. Do not inject into areas where the skin is tender, bruised, or affected by psoriasis.
Missed Dose: If a dose is missed, administer it as soon as possible on the same day. If the next scheduled dose is due the following day, skip the missed dose. Do not double the dose.
3. Mechanism of Action
TNF-Binding: Etanercept is a recombinant human soluble p75 tumor necrosis factor receptor fusion protein.
Inflammation Blockade: It acts as a decoy receptor by binding with high affinity to TNF-α and lymphotoxin-α (TNF-β), blocking their interaction with cell surface TNF receptors.
Downstream Effects: This inhibition reduces the release of pro-inflammatory cytokines and mediators, thereby alleviating joint inflammation, skin lesions, and preventing structural damage.
4. Safety and Warnings
Infections: Serious infections (including tuberculosis, invasive fungal infections, and bacterial/viral/septicemia) have been reported. Screen for latent tuberculosis and hepatitis B prior to initiation. Discontinue if a serious infection develops.
Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescents receiving TNF blockers.
Heart Failure: New onset or worsening of congestive heart failure has been observed; avoid use in severe heart failure.
Immunogenicity: Development of antibodies may reduce efficacy or cause hypersensitivity reactions.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Injection site reactions (erythema, itching, pain, swelling), upper respiratory tract infections, headache, and rash.
Hematologic Abnormalities: Neutropenia and thrombocytopenia have been reported.
Clinical Research Highlights: Multiple pivotal Phase 3 trials demonstrated significant improvements in ACR response rates (rheumatoid arthritis), ASDAS scores (ankylosing spondylitis), and PASI scores (psoriasis) compared to placebo.
6. Drug Interactions
Live Vaccines: Concomitant use with live or attenuated vaccines (e.g., MMR, varicella) is contraindicated due to the risk of infection.
Anakinra: Concomitant use with anakinra increases the risk of serious infections and neutropenia and is not recommended.
Abatacept: Concomitant use increases the risk of serious adverse events without proven additional benefit and is not recommended.
Other Immunosuppressants: May increase the overall risk of infection when used with other immunosuppressive agents.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Etanercept. Excipients: Sucrose, mannitol, sodium chloride, polysorbate 20, water for injection.
Appearance: Clear, colorless to pale yellow solution.
Packaging: 25 mg/0.7 mL single-use prefilled syringe or autoinjector.
Storage: Store in a refrigerator at 2°C to 8°C. Do not freeze or shake.